Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:33 2024-05-03 am EDT			5-day change	1st Jan Change
2,061 ^DKK	+5.91%		+5.45%	-4.36%

May. 03	GENMAB : A good start to 2024; guidance unchanged
May. 03	Genmab Posts Q1 Net Profit Surge; Revenue Jumps	MT

Tranche Update on Genmab A/S's Equity Buyback Plan announced on February 14, 2024.

March 18, 2024 at 05:49 am EDT

From February 14, 2024 to March 15, 2024, the company has repurchased 190,000 shares, representing 0.29% for DKK 378.72 million. With this, the company has completed the repurchase of 190,000 shares, representing 0.29% for DKK 378.72 million under the buyback announced on February 14, 2024.

Latest news about Genmab A/S

GENMAB : A good start to 2024; guidance unchanged	May. 03
Genmab Posts Q1 Net Profit Surge; Revenue Jumps	May. 02	MT
Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance	May. 02	MT
Transcript : Genmab A/S, Q1 2024 Earnings Call, May 02, 2024	May. 02
Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer	Apr. 30	MT
Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment	Apr. 29	MT
Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer	Apr. 29	CI
Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug	Apr. 29	DJ
Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug	Apr. 16	MT
Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024	Apr. 16	CI
Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ
Health Care Flat on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	Apr. 03	DJ
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET	Apr. 03	DJ
Global markets live: Swiss Re, Intel, Walt Disney, Paramount, Microsoft...	Apr. 03
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET	Apr. 03	DJ
Correction to Genmab Article	Apr. 03	DJ
Genmab: acquisition of ProfoundBio greeted without emotion	Apr. 03	CF
News Highlights : Top Company News of the Day - Wednesday at 7 AM ET	Apr. 03	DJ
Genmab A/S Re-Affirms Revenue Guidance for the Year 2024	Apr. 03	CI
Transcript : Genmab A/S, ProfoundBio - M&A Call	Apr. 03
European Midday Briefing : Stocks Continue to Struggle Despite Cooling Inflation	Apr. 03	DJ
News Highlights : Top Company News of the Day - Wednesday at 5 AM ET	Apr. 03	DJ
Genmab Strengthens Oncology Portfolio With $1.8 Billion Acquisition of ProfoundBio	Apr. 03	DJ
Genmab Looks to Expand Clinical Pipeline with $1.8 Billion Purchase of Cancer-focused ProfoundBio	Apr. 03	MT

Chart Genmab A/S

Duration

Period

More charts

Company Profile

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.

Sector

Biotechnology & Medical Research

Calendar

2024-08-01 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 01:08 pm EDT

More Strategies

Ratings for Genmab A/S

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2,061 DKK

Average target price

2,474 DKK

Spread / Average Target

+20.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENMAB A/S	-4.36%	19.25B
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B
VIKING THERAPEUTICS, INC.	+313.59%	8.49B
LEGEND BIOTECH CORPORATION	-24.53%	8.26B

Bio Therapeutic Drugs